Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients](https://i1.wp.com/ml-eu.globenewswire.com/media/NTJlMDkyZjktNGMwNi00N2YyLTkyZmQtZTIwMWJlNzgxOWYyLTEwMTI2MjEtMjAyNS0wNi0xNS1lbg==/tiny/F-Hoffmann-La-Roche-Ltd.png?w=420&resize=420,280&ssl=1 "[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients")
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-risk for the use of Elevidys…
FANTASTICS from EXILE TRIBE, Former Taipei City Tourism Ambassadors, to Present BACK TO THE MEMORIES PART5 via Livestream!
Presenting a special experience to fans around the world.TOKYO--(BUSINESS WIRE)--ZAIKO will begin…
THE WORLD’S 50 BEST RESTAURANTS ANNOUNCES THE 51-100 LIST FOR 2025
LONDON, June 5, 2025 /PRNewswire/ -- The World's 50 Best Restaurants 2025,…
Roches Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
Simplified storage and administration of new tablet formulation may provide greater freedom…
Blokees Initial Release Minions Mokoo Series: Minions-N-Disguise, Becomes a Banana Day Hotspot
SHANGHAI, June 3, 2025 /PRNewswire/ --Â On June 1, 2025, the 2025 Minions…
Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27%…
Addex Convenes Annual General Meeting 2025
June 03, 2025 01:00 ET Â | Source: Addex Therapeutics Geneva, Switzerland, June…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…
WISeKey to Present at Maxim Tech Conference Discover the Innovations Reshaping Tomorrow on June 3 at 8:30am ET
June 02, 2025 01:00 ET Â | Source: Wisekey International Holding Ltd. WISeKey…